Indomethacin has a potent antiviral activity against SARS coronavirus

Antiviral Therapy

Volumn 11, Issue 8, 2006, Pages 1021-1030

  Amici, Carlo ^a   Di Caro, Antonino ^b   Ciucci, Alessandra ^a   Chiappa, Lucia ^a   Castilletti, Concetta ^b   Martella, Vito ^c   Decaro, Nicola ^c   Buonavoglia, Canio ^c   Capobianchi, Maria R ^b   Santoro, M Gabriella ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; PROSTAGLANDIN SYNTHASE; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BIOSAFETY; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS EPITHELIUM; NONHUMAN; NORTHERN BLOTTING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SYNTHESIS; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VERO CELL; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; ASPIRIN; CELL LINE; CERCOPITHECUS AETHIOPS; CORONAVIRUS INFECTIONS; CORONAVIRUS, CANINE; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FECES; HUMANS; INDOMETHACIN; INTERFERON-ALPHA; RIBAVIRIN; RNA, VIRAL; SARS VIRUS; VIRUS REPLICATION;

EID: 33845680708     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348:1967-1976.
2. Rota P, Oberste M, Monroe S, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300:1394-1399.
3. Lai MMC, Holmes KV. Coronaviridae: the viruses and their replication. In Field's Virology, 4th edn 2001; pp. 1163-1185. Edited by DM Knipe & P Howley. Philadelphia, USA: Lippincott, Williams & Wilkin.
4. Peiris JSM, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nature Med 2004; 10:588-597.
5. Skowronski DM, Astell C, Brunham RC, et al. Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med 2005; 56:357-381.
6. Santoro MG. Antiviral activity of cyclopentenone prostanoids. Trends Microbiol 1997; 276:276-281.
7. Morimoto RI, Santoro MG. Stress-inducible responses and heat shock proteins: new pharmacologic targets for cytoprotection. Nature Biotechnol 1998; 16:833-838.
8. Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 2000; 403:103-108.
9. Santoro MG, Rossi A, Amici C. NF-κB and virus infection: who controls whom. EMBO J 2003; 22:2552-2560.
10. Bernasconi D, Amici C, La Frazia S, Ianaro A, Santoro MG. The IκB kinase is a key factor in triggering influenza A virus-induced inflammatory cytokine production in airway epithelial cells. J Biol Chem 2005; 280:24127-24134.
11. Amici C, Belardo G, Rossi A, Santoro MG. Activation of IκB kinase by herpes simplex virus type 1. A novel target for anti-herpetic therapy. J Biol Chem 2001; 276:28759-28766.
12. Stroher U, DiCaro A, Li Y, et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J Infect Dis 2004; 189:1164-1167.
13. Rozera C, Carattoli A, De Marco A, Amici C, Giorgi C, Santoro MG. Inhibition of HIV-1 replication by cyclopentenone prostaglandins in acutely infected human cells: evidence for a transcriptional block. J Clin Invest 1996; 97:1795-1803.
14. Decaro N, Pratelli A, Campolo M, et al. Quantitation of canine coronavirus RNA in the faeces of dogs by TaqMan RT-PCR. J Virol Methods 2004; 119:145-150.
15. Castilletti C, Bordi L, Lalle E, et al. Coordinate induction of IFN-α and -γ by SARS-CoV in the absence of virus replication. Virology 2005; 10:163-169.
16. Pratelli A, Elia G, Martella A, et al. Prevalence of canine coronavirus antibodies by an enzyme-linked immunosorbent assay in dogs in the south of Italy. J Virol Methods 2002; 102:67-71.
17. Pratelli A, Tinelli A, Decaro N, et al. Safety and efficacy of a modified-live canine coronavirus vaccine in dogs. Vet Microbiol 2004; 99:43-49.
18. Fujii T, Nakamura T, Iwamoto A. Current concepts in SARS treatment. J Infect Chemother 2004; 10:1-7.
19. Rane A, Oelz O, Frolich TC, et al. Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clin Pharmacol Ther 1978; 23:658-668.
20. Arai I, Mao GP, Otani K, Konno S, Kikuchi S Olmarker K. Indomethacin blocks the nucleus pulposus-induced effects on nerve root function. An experimental study in dogs with assessment of nerve conduction and blood flow following experimental disc herniation. Eur Spine J 2004; 13:691-694.
21. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Adv Exp Med Biol 1997; 433:131-138.
22. Tegerder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15:2057-2072.
23. Yang ZY, Werner HC, Kong WP, et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA 2005; 102:797-801.